Pharma: Page 4
-
Getty Images via Getty Images
A new way of determining a drug’s value — with health equity in mind
Quality-adjusted life years are an important tool to frame a drug’s cost effectiveness, but they leave out other determinants of health.
By Michael Gibney • Sept. 10, 2024 -
Getty Images via Getty Images
Huntington’s disease R&D is regaining ground after several disappointments
Setbacks haven’t stopped advances by biotechs and pharmas working on new drugs for the inherited brain disorder.
By Kelly Bilodeau • Sept. 9, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineCommercialization, marketing and social media
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
By PharmaVoice staff -
Scott Olson via Getty Images
Lilly lays down $1B to be ‘first in biology’ with obesity gene therapies
The deal, which targets metabolic diseases, is one of a few by Big Pharma to develop lncRNA therapies.
By Amy Baxter • Sept. 9, 2024 -
Stock via Getty Images
What 3 layoff stories reveal about pharma’s troubles
The factors driving the industry’s layoffs — and what could help turn the tide.
By Meagan Parrish • Sept. 6, 2024 -
Permission granted by Merck & Co.
Big Pharma is often media shy. Merck’s chief comms officer is hoping to change that.
Cristal Downing is helping Merck & Co. buck pharma’s zipped-lip status quo and usher in a “new era” of openness, transparency and “overt communication.”
By Alexandra Pecci • Sept. 5, 2024 -
Permission granted by Pfizer
A plucky biotech threatening Pfizer’s grip on the Prevnar vaccine market
Results from Vaxcyte’s clinical pneumococcal vaccine study showed the smaller company could take on Pfizer’s legendary blockbuster.
By Michael Gibney • Sept. 4, 2024 -
Stock via Getty Images
Pharma’s ‘it’ therapy — a new drug class gaining steam
More companies are investing in protein degraders, which leverage a unique approach to harnessing the immune system in cancer, neurological diseases and more.
By Kelly Bilodeau • Sept. 4, 2024 -
Sarah Silbiger via Getty Images
FDA adcomm reform talks heat up
As the agency considers eliminating adcomm votes from the approval process, members vie to have their voices heard.
By Amy Baxter • Sept. 3, 2024 -
Stock via Getty Images
Is anyone taking the world’s priciest drugs?
A slew of breakthrough gene therapies won FDA approval in recent years — but high price tags haven’t always yielded big returns.
By Meagan Parrish • Aug. 30, 2024 -
iStock via Getty Images
As pharma’s AI revolution gets underway, ‘hallucinations’ pose a great risk
While AI, machine learning and large language models can distill huge amounts of information, they sometimes make mistakes. New technologies could rebuild that trust.
By Michael Gibney • Aug. 27, 2024 -
Permission granted by Takeda Pharmaceuticals
Q&A // First 90 DaysWith a new oncology R&D head, Takeda revamps its strategy
The company is using a “three-by-four” approach to sharpen its cancer R&D aims.
By Alexandra Pecci • Aug. 27, 2024 -
PierreDesrosiers via Getty Images
Pharmas’ IRA court losses mount. They keep pursuing them.
The final drug prices for Medicare’s negotiation program have been published, but pharma companies continue to push their legal strategies.
By Amy Baxter • Aug. 26, 2024 -
Mario Tama/ via Getty Images
As a new mpox strain gains ground, a key drug stumbles in the clinic
Despite the disappointing results, the drug’s developer, Siga Therapeutics, said there’s more to the story.
By Kelly Bilodeau • Aug. 26, 2024 -
Getty Images via Getty Images
Will the IRA squash new drugs? Those worries are likely exaggerated, studies say.
There’s no link between revenue and R&D from smaller biotechs, and that’s where most innovation comes from, according to new studies.
By Alexandra Pecci • Aug. 22, 2024 -
Drew Angerer via Getty Images
Pharma’s concerns pile up months after Supreme Court’s landmark Chevron decision
The Supreme Court case added another layer of uncertainty on the regulatory front and opened up the Inflation Reduction Act to more legal attacks.
By Amy Baxter • Aug. 21, 2024 -
Courtesy of 23andMe
Q&A23andMe inches closer to cancer immunotherapy, guided by its genetic database
Dr. Jennifer Low, head of 23andMe’s therapeutics division, is taking the company into new territory with a potential cancer treatment that targets a unique pathway.
By Michael Gibney • Aug. 20, 2024 -
hapabapa via Getty Images
Novo plans new plant as it races to meet drug demand
The new factory, which Novo is committing some $220 million to build, will supply raw materials for the company’s chronic disease medicines.
By Ned Pagliarulo • Aug. 19, 2024 -
Stock via Getty Images
BMS’ KarXT nears schizophrenia approval, but AbbVie and others wait in the wings
With fewer side effects, the new wave of upcoming drugs could improve patient adherence, and the competition for a large projected market is getting fierce.
By Kelly Bilodeau • Aug. 19, 2024 -
Kena Betancur via Getty Images
The drugs hit hardest by Medicare price negotiations
The final negotiations slash drug prices between 38% and 79% for Medicare’s 2026 calendar year.
By Amy Baxter • Aug. 16, 2024 -
Scott Olson via Getty Images
Medicare reveals results of drug price negotiations
The agency said the first round of pricing talks, which involved drugs like the blood thinners Eliquis and Xarelto, will result in $6 billion in savings for taxpayers.
By Ned Pagliarulo • Aug. 15, 2024 -
Permission granted by Reed Tuckson
Lessons from COVID: Tuskegee impacts still erode trust in healthcare, but hope shines through
A long-time leader in public health and outreach to people of color, Dr. Reed Tuckson offers the lessons he learned from the COVID pandemic and how pharma can better serve those communities.
By Michael Gibney • Aug. 15, 2024 -
Andreas Rentz via Getty Images
Can BioNTech sustain a post-COVID mRNA pipeline? Oncology is the next hope.
The German biotech is leveraging its mRNA platforms to develop a new class of cancer treatments that are necessary to lift the company’s flagging sales.
By Amy Baxter • Aug. 14, 2024 -
Permission granted by Immunic Therapeutics
A potential MS ‘game changer’ could bring more safety to the table — even against viruses
Immunic’s treatment has anti-inflammation, neuroprotection and antiviral effects plus a ‘benign’ safety profile that even seems to lower the risk of COVID-19 infection.
By Alexandra Pecci • Aug. 13, 2024 -
Stock via Getty Images
M&A is ready to explode, and that’s good news for pharma layoffs
Deals driven by obesity meds are fueling an M&A comeback, driving the industry to take fewer cost-cutting measures.
By Kelly Bilodeau • Aug. 12, 2024 -
Spencer Platt via Getty Images
Pharma execs react to final drug price negotiations with Medicare
Here’s what the leaders of the companies with the 10 drugs in the first wave of price negotiations with Medicare said about how the new prices will impact their portfolio.
By Amy Baxter • Aug. 9, 2024
Previous
